Blog Archives

New treatments for multiple sclerosis and inflammatory arthritis approved

March 31, 2019 – The American Food and Drug Administration (FDA) has just approved  drugs for two rather problematic neurological conditions, namely multiple sclerosis (i.e., Cladribine (Mavenclad)) and non-radiographic axial spondyloarthritis (i.e., Certolizumab pegol (Cimzia)), offering patients with these conditions urgently need additional therapy options. FDA approves new oral treatment for multiple sclerosis

The FDA approved Cladribine (Mavenclad) tablets to treat relapsing forms of multiple sclerosis (MS ) in adults,

Read more ›

Tags: , , , , , , , ,

Febuxostat (Uloric) and its problem with cardiovascular mortality

January 16, 2109 – Despite drug safety problems of cardiovascular mortality with Febuxostat (Uloric), the benefits might still be seen to outweigh risks for selected gout patients. This notion may become more and disputed over time, however, for obvious reasons.

Read more ›

Tags: , , , , , , , ,

Abilify MyCite, the first digital pill. Where does all that silicone go?

November 16, 2017 – The American Food & Drug Administration (FDA) just approved Ability MyCite,  a pill with a sensor that digitally tracks if patients have ingested their medication. This is a very first in its class at the new age of digital health.

Read more ›

Tags: , , , , , , , , , ,

Axicabtagene Ciloleucel (Yescarta) gene therapy for diffuse large B-cell lymphoma

October 19, 2017 – The American  Food & Drug Administration (FDA) just approved Axicabtagene Ciloleucel (Yescarta), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment.

Read more ›

Tags: , , , , , , , , , , , , , ,

The first gene therapy FDA approved in the US

September 3, 2017 – For a very first time, the American Food & Drug Administration (FDA) has approved a gene therapy for the United States (US) in that it approved CAR T-cell therapy to treat certain children and young adults with B-cell acute lymphoblastic leukemia (B-cell ALL).

Read more ›

Tags: , , , , , , , , , , ,

Enasidenib (Idhifa): Targeted treatment for relapsed or refractory AML

August 02, 2017 – This is another cornerstone in the fight against acute myeloid leukemia (AML): The American Food and Drug Administration (FDA) just approved Enasidenib (Idhifa) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation.

Read more ›

Tags: , , , , , , , , ,

Brodalumab (Siliq) with a fatal touch: New psoriasis drug approved

February 16, 2017 – The American Food & Drug Administration (FDA) just approved Brodalumab (Siliq) to treat adults with moderate-to-severe plaque psoriasis. Brodalumab (Siliq) is administered as an injection. Brodalumab (Siliq) is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream,

Read more ›

Tags: , , , , , , , ,

FDA warns about the risk of HBV reactivation in patients treated with DAA for HCV-infection

October 05, 2016 – Here, we make available to our readers a Drug Safety Communication by the American Food & Drug Administration (FDA), where FDA warns about the risk of hepatitis B virus (HBV) reactivation in some patients treated with direct-acting antivirals (DAA) for hepatitis hepatitis-c-iC virus (HCV)-infection.

Read more ›

Tags: , , , , , , , , , , ,

The opioid epidemic: Is there a never ending sad story?

September 01, 2016 – This is what we learned this morning and sadly, the issue of opioids use in the population along with its fatal outcomes seems never to stop.  The American Food & Drug Asministation (FDA) requires, according to a press release this morning,

Read more ›

Tags: , , ,

Necitumumab (Portrazza) approved for the treatment of advanced squamous non-small cell lung cancer (NSCLC)

November 28, 2015 – The American Food and Drug Administration (FDA) just approved Necitumumab (Portrazza) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer.

Read more ›

Tags: , , , , , , ,

thasso: conditions

thasso: newest tweets

thasso: recent comments

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Discovery of life in solid rock deep beneath sea may inspire new search for life on Mars April 2, 2020
    Newly discovered single-celled creatures living deep beneath the seafloor have provided clues about how to find life on Mars. These bacteria were discovered living in tiny cracks inside volcanic rocks after researchers perfected a new method cutting rocks into ultrathin slices to study under a microscope. Researchers estimate that the rock cracks are home to […]
  • Geneticists are bringing personal medicine closer to recently admixed individuals April 2, 2020
    A new study in Nature Communications proposes a method to extend polygenic scores, the estimate of genetic risk factors and a cornerstone of the personalized medicine revolution, to individuals with multiple ancestral origins. The study was led by Dr. Davide Marnetto from the Institute of Genomics of the University of Tartu, Estonia and coordinated by […]
  • Breast density, microcalcifications, and masses may be heritable traits April 2, 2020
    An analysis of a large Swedish cohort revealed that breast density, microcalcifications, and masses are heritable features, and that breast density and microcalcifications were positively associated with a genetic predisposition to breast cancer, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.
  • Impacts of cover crop planting dates on soil properties after 4 years April 2, 2020
    Low biomass production limits cover crop effects on soils.
  • A next-generation sensor network for tracking small animals April 2, 2020
    A newly developed wireless biologging network (WBN) enables high-resolution tracking of small animals, according to a study published April 2 in the open-access journal PLOS Biology by Simon Ripperger of the Leibniz Institute for Evolution and Biodiversity Science, and colleagues.
Top